Author

W Zhang

Institution: KU Leuven

Observed institutions: Takeda (United States), KU Leuven

OpenAlex ID: A5017294654

OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study

2020 · S Vermeire, W Sandborn, et al. · Journal of Crohn s and Colitis · 11

DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2

2020 · C Chen, M Rosario, et al. · Journal of Crohn s and Colitis · 3

OP12 Therapeutic antibody clearance better predicts endoscopic outcomes than trough concentrations in patients with Crohn’s disease

2025 · Z Wang, Y Hoffert, et al. · Journal of Crohn s and Colitis · 1

P0865 Impact of assay on the predictive performance of model-informed precision dosing of ustekinumab in patients with Crohn’s disease

2025 · W Zhang, T Dervieux, et al. · Journal of Crohn s and Colitis

P290 Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in Inflammatory Bowel Disease

2021 · R Ungaro, H Kadali, et al. · Journal of Crohn s and Colitis

Works count: 5

Citation count: 15

H-index: 2

I10-index: 1